Shionogi taps Nipro expertise to bolster Rapiacta promotion
This article was originally published in Scrip
Executive Summary
Amid an increasingly competitive environment, Shionogi is bolstering the promotional power for its rapid-acting flu product Rapiacta (peramivir; licensed from BioCryst Pharmaceuticals) in Japan through an alliance with the medical products company Nipro.